Durable tumour responses following primary high dose induction with mistletoe extracts: Two case reports

European Journal of Integrative Medicine

Volumn 2, Issue 2, 2010, Pages 63-69

  Orange, M ^a   Fonseca, M ^a   Lace, A ^a   von Laue, H B ^b   Geider, S ^c  

^a Park Attwood Clinic   (United Kingdom)

^b Onkologische Schwerpunktpraxis ^*  (Germany)

^c Camphill Medical Practice   (United Kingdom)

Author keywords

Febrile induction; In situ priming; Intratumoural; Intravenous; Mistletoe therapy

Indexed keywords

VISCUM ALBUM EXTRACT;

ACTINIC KERATOSIS; ADULT; ANAMNESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOWEN DISEASE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CASE REPORT; CHILL; COMORBIDITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG ISOLATION; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMORRHOID; HISTOPATHOLOGY; HUMAN; INJECTION SITE INFLAMMATION; MERKEL CELL TUMOR; POSTMENOPAUSE; PRIORITY JOURNAL; RECTUM CARCINOMA; RIGOR; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; VISCUM ALBUM;

EID: 77953198684     PISSN: 18763820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eujim.2010.04.001     Document Type: Article

References (32)

1. In: Büssing A. (Ed). Mistletoe. The genus viscum (2000), Hardwood Academic Publishers, Amsterdam ISBN 90-5823r-r092-9
2. Büssing A. Immune modulation using mistletoe (Viscum album L.) extracts iscador influencing cell function through subcutaneous and intravenous application. Arzneim.-Forsch./Drug Res. 56 6a (2006) 508-515
3. Matthes H., Buchwald D., Kroez M., and Schad F. Integrative Therapie-moeglichkeiten des inoperablen Pankreaskarzinoms-eine Uebersicht. Dtsch Zeitsch Onkologie 40 3 (2008) 106-110
4. Kienle G.S., and Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 12 3 (2007) 103-119
5. Debus M. Intralesional mistletoe therapy. Der Merkurstab 62 4 (2009) 304-305
6. Lemos B., and Nghiem P. Merkel cell carcinoma: more deaths but still no pathways to blame. J Invest Dermatol 127 (2007) 2100-2103
7. Pectasides D., Pectasides M., and Economopoulos T. Merkel cell cancer of the skin. Ann Oncol 17 (2006) 1489-1495
8. Garneski K.M., and Nghiem P. Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol 57 (2007) 166-169
9. Sais G., Admella C., and Solerà T. Spontaneous regression in primary cutaneous neuroendocrine (Merkel cell) carcinoma: a rare immune phenomenon?. J Eur Acad Dermatol Venereol 16 (2002) 81-94
10. Büssing A., and Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res 19 (1999) 23-28
11. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 92 (2000) 205-216
12. Trotti A., Byhardt R., Stetz J., Gwede C., Corn B., Fu K., et al. Common toxicity criteria: version 2.0. Int J Radiat Oncol Biol Phys 47 1 (2000) 13-47
13. American Cancer Society. Breast cancer facts & figures 2007-2008 (2007), American Cancer Society Inc., Atlanta
14. Carmichael A.R., Bendall S., Lockerbie L., Prescott R., and Bates T. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol 28 (2002) 388-391
15. Irvine T., Allen D.S., Gillett C., Hamed H., and Fentiman I.S. Prognosis of synchronous bilateral breast cancer. Br J Surg 96 (2009) 376-380
16. Challis G.B., and Stam H.J. The spontaneous regression of cancer. Acta Oncol 29 5 (1990) 545-550
17. den Brok M.H.M.G.M., Sutmuller R.P.M., van der Voort R., Bennink E.J., Carl G., Figdor C.G., et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64 (2004) 4024-4029
18. Crittenden M.R., Thanarajasingam U., Vile R.G., and Gough M.J. Intratumoral immunotherapy: using the tumour against itself. Immunology 114 (2005) 11-22
19. Sanchez-Perez L., Gough M., Qiao J., Thanarajasingam U., Kottke T., Ahmed A., et al. Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells. Gene Ther 14 (2007) 998-1009
20. Thong P.S.-P., Ong K.-W., Goh N.S.-G., Kho K.-W., Manivasager V., Bhuvaneswari R., et al. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol 8 (2007) 950-952
21. Dr. med Kraft. Praktische Erfahrungen ueber die Behandlung der Krebskrankheit mit Mistelextrakten. Muench Med Wschr 50 (1940) 1395-1399
22. Röseler W.-B. Zur Behandlung inoperabler Carcinome. Der Krankenhausarzt in Wissenshaft, Recht und Wirtschaft 3 3 (1950) 125-127
23. Scheffler A., Mast H., Fischer S., and Metelmann H.R. Komplette Remission eines Mundhöhlenkarzinoms nach alleiniger Mistelbehandlung (Complete remission of oro-paryngeal carcinoma after sole mistletoe treatment). In: Scheer R., Becker H., and Berg P.A. (Eds). Grundlagen der Misteltherapie-Aktueller Stand der Forschung und klinische Anwendung (1996), Hippokrates Verlag, Stuttgart 453-466
24. Stumpf C., Ramirez-Martinez S., Becher A., Stein G.M., Biissing A., and Schietzel M. Intratumorale Mistelapplikation bei stenosierendem Rezidiv eines Cardia-Carzinoms. Erfahrungsheilkunde 46 (1997) 509-513
25. Matthes H. Intralesionale Mistelinjektionen in Lebermetastasen bei kolorektalem Karzinom und in das primaere Hepatozellulaer Karzinom (HCC) [Abstract]. Merkurstab 50 (1997) 41
26. Mahfouz M., Chaleb H., Hamza M.R., Fares L., Moussa L., Muostafua A., et al. Multicenter open labeled clinical study in advanced breast cancer patients. A preliminary report. J Egypt Nat Cancer Inst 11 3 (1999) 221-227
27. Nabrotzki M., and Scheftler A. Komplette Remission nach intratumoraler Misteltherapie eines Duodenum-Karzinoni-Rezidivs. In: Scheer R., Bauer R., Becker H., Berg P.A., and Fintelmann V. (Eds). Die Mistel in der Tumortherapie. Crundlagenforschung und Klinik (2001), KVC Verlag, Essen 413-422 (in German)
28. Matthes H., Buchwald D., Kroez M., and Schad F. Integrative Therapiemoeglichkeiten des inoperablen Pankreaskarzinoms. Dtsch Ztschr f Onkologie 40 (2008) 106-110
29. Coley-Nauts H.C., Fowler G., and Bogatko F.H. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man. Acta Med Scand 145 (1953) 5-102
30. Hobohm U. Fever therapy revisited. Br J Cancer 92 (2005) 421-425
31. Decker W.K., and Safdar A. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev 20 4 (2009) 271-281
32. Falk M.H., and Issels R.D. Hyperthermia in oncology. Int J Hyperthermia 17 (2001) 1